An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer

NCT00748358 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Prostatic Neoplasms
Neoplasms, Hormone-Dependent
Tumor Markers, Biological
Survival Rate
Disease-Free Survival

Interventions

DRUG: sunitinib

Sponsor

Assistance Publique - Hôpitaux de Paris